CTI BioPharma Gross Profit

CTI BioPharma (CTIC) currently reports a gross profit of $71M as of March 2023. That compares with $2M in the prior-year period — up 3435.4% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore CTI BioPharma's gross profit history and peer comparisons.

CTI BioPharma's gross profit increased from $2M to $71M — a 3435.4% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CTI BioPharma's gross profit of $71M is lower than the Healthcare sector average of $66B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

CTI BioPharma reported $71M in gross profit as of March 2023. That compares with $2M in the prior-year period — up 3435.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $71M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for CTI BioPharma, and consider following CTIC for alerts when major investors trade the stock.